Clinical trials
Participation clinical trials
Below are recruiting participation clinical trials, each written for real people, not researchers. We’re tracking 2,290 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06975787RecruitingPhase 1
A New Bispecific Antibody for Lupus Nephritis
This trial is testing a new type of medicine called a 'bispecific antibody' for people whose lupus nephritis has not responded to standard treatments or keeps coming back. The goal is to find a safe dose that might better control the kidney inflammation.
San Francisco, CaliforniaAges 18–60 - NCT06979102Enrolling by invitation
Stoma care teaching for new ileostomy patients and caregivers
This trial tests a teaching method that uses a real patient to help new ileostomy patients and their unpaid caregivers learn stoma care and management. It aims to improve confidence and skills.
Ankara, TurkeyAges 18 years+ - NCT06975020Recruiting
Comparing biomarkers in regular cannabis users vs. non-users
This study compares biological markers between people who use cannabis regularly and those who do not, to understand how cannabis affects the body.
BaselAges 18–65 - NCT06963021RecruitingPhase 3
Study of NBI-1065845 for depression that hasn't fully responded to treatment
This trial tests an investigational drug called NBI-1065845 added to your current antidepressant. It is for people with moderate to severe depression or persistent depressive disorder who have not improved enough with oral antidepressants alone.
Chino, CaliforniaAges 18 years+ - NCT06971939RecruitingPhase 4
Long-term safety of NT-501 implant for MacTel type 2
This study checks the long-term safety and effectiveness of the NT-501 implant for people with MacTel type 2. It is for people who have already been in an earlier NT-501 study, whether they got the real implant or a sham procedure.
La Jolla, CaliforniaAges 18 years+ - NCT06962332RecruitingPhase 1
Study of Zanzalintinib in People with Moderate Liver Problems
This trial looks at how a drug called Zanzalintinib acts in people with moderate liver impairment compared to healthy volunteers. It aims to ensure the drug is safe and at the right dose for people with liver issues.
Orlando, FloridaAges 18–75 - NCT06963281RecruitingPhase 1
Study of an experimental drug for late-stage solid tumors
This trial tests an experimental drug called IBI3020 for people with advanced solid tumors that have not responded to standard treatments. It aims to see if the drug is safe and effective for these patients.
Phoenix, ArizonaAges 18–75 - NCT06966024RecruitingPhase 1
Study of DCC-2812 for advanced genitourinary cancers
This trial tests an experimental pill called DCC-2812 for people with advanced kidney, bladder, or prostate cancer. The goal is to see if it is safe and if it might help shrink tumors or slow the cancer's growth.
Boston, MassachusettsAges 18 years+ - NCT06969430RecruitingPhase 1/Phase 2
Debio 1562M for relapsed or refractory AML
This trial tests a new drug called Debio 1562M for people with AML that has not responded to treatment or has come back. It aims to see if the drug is safe and can help fight the leukemia.
Duarte, CaliforniaAges 18 years+ - NCT06965374Recruiting
Study of a new Parkinson's injection and quality of life
This study is looking at how a new continuous 24-hour injection treatment (foslevodopa/foscarbidopa) affects quality of life in people with advanced Parkinson's disease. It is a real-world study, meaning you just take the medication as your doctor prescribes, and researchers observe the results.
Troina, EnnaAges 18 years+ - NCT06966401RecruitingPhase 3
Long-term safety study of a new depression treatment
This study tests a new oral medication (NBI-1065845) added to your current antidepressant to see if it's safe and tolerable over a long period for people with depression that hasn't fully responded to treatment.
Huntsville, AlabamaAges 18 years+ - NCT06971731RecruitingPhase 3
JNT-517 pill for adults with PKU
This trial tests a new pill called JNT-517 to see if it can lower high blood phenylalanine (Phe) levels in people with PKU. You may be a good fit if you have PKU, are at least 18, and can stick to a steady diet.
Los Angeles, CaliforniaAges 18 years+ - NCT06968871Recruiting
Gentler Pap test for cervical cancer screening
This trial tests a new, gentler Pap test to see if it makes screening more comfortable and easier for women. If you're a woman 25 or older and not pregnant or on your period, you might be able to join.
DouliuAges 25 years+ - NCT06962930Recruiting
Online coaching to help people with Parkinson's stay active
This study tests whether online coaching sessions can help people with Parkinson's disease in Qatar become more physically active. You'll receive coaching from home, so it's convenient and safe.
DohaAges 18 years+ - NCT06754644RecruitingPhase 3
Study of QL2107 plus chemo vs. Keytruda for advanced lung cancer
This trial tests a new drug, QL2107, combined with chemotherapy, compared to the standard drug Keytruda (pembrolizumab) with chemotherapy. It is for people with stage IV non-squamous non-small cell lung cancer that does not have certain gene mutations (EGFR or ALK).
Jinan, ShandongAges 18–75 - NCT06928350Recruiting
Normal esophagus readings in healthy Indian adults
This trial is studying normal acid and fluid movement in the esophagus of healthy people in India. It will help doctors better understand what is typical, which may improve care for people with acid reflux or other swallowing issues.
Hyderabad, TelanganaAges 18–50 - NCT06961747RecruitingPhase 1
Zilucoplan levels in breast milk of healthy nursing mothers
This study measures how much of the drug zilucoplan passes into breast milk. Healthy nursing mothers who are already planning to stop breastfeeding can take part to help understand how the drug is processed.
San Antonio, TexasAges 18 years+ - NCT06960395RecruitingPhase 1
Study of VIR-5525 alone or with pembrolizumab for advanced solid tumors
This trial tests a new drug called VIR-5525, either alone or combined with pembrolizumab (an immunotherapy), for people with advanced solid tumors that have not responded to other treatments or cannot undergo standard therapy. It focuses on certain cancer types and tumors with a specific genetic change (EGFR amplification).
Scottsdale, ArizonaAges 18 years+ - NCT06959706RecruitingPhase 1
Study of TGW101 for advanced solid tumors
This trial tests a new drug called TGW101 for people with certain advanced solid tumors that have not responded to standard treatments. The goal is to see if it is safe and may help shrink tumors.
Scottsdale, ArizonaAges 18 years+ - NCT06953960RecruitingPhase 1/Phase 2
Surzetoclax for multiple myeloma
This trial tests a new oral drug, surzetoclax, given alone or with other myeloma treatments, in adults whose myeloma has come back or stopped responding to treatment. It may help slow the disease and improve symptoms.
Los Angeles, CaliforniaAges 18 years+ - NCT06951880RecruitingPhase 1
Safety of AZD4916 in healthy volunteers
This study tests a new drug called AZD4916 in healthy people to see if it's safe and how the body processes it. It may help decide if the drug is safe enough for future studies.
Glendale, CaliforniaAges 18–55 - NCT06947928RecruitingPhase 2/Phase 3
Vaccine plus immunotherapy for Merkel cell cancer
This trial tests an experimental vaccine (IFx-Hu2.0) followed by the immunotherapy drug pembrolizumab in people with advanced Merkel cell carcinoma who have not been treated with checkpoint inhibitors before. The goal is to see if this combination helps shrink or control the cancer.
Los Angeles, CaliforniaAges 18 years+ - NCT06943755RecruitingPhase 2/Phase 3
Zanzalintinib vs Everolimus for Neuroendocrine Tumors
This trial compares a new targeted therapy (zanzalintinib) with an existing drug (everolimus) for people with advanced neuroendocrine tumors (NETs). It aims to see which treatment works better and may offer a new option for patients whose cancer has grown despite previous treatments.
Birmingham, AlabamaAges 18 years+ - NCT06948448RecruitingPhase 2
New treatment for advanced colorectal cancer with PD-L1 biomarker
This trial tests a new drug (ONO-4578) combined with standard chemotherapy and immunotherapy for people with advanced colorectal cancer that has not been treated before and has a specific marker called PD-L1. The goal is to see if this combination works better than the usual treatment.
Phoenix, ArizonaAges 18 years+
Hear when a new Participation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for participation?
- Yes. Clin2 currently lists 2,290 recruiting participation studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a participation trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a participation trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.